These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 31690270)

  • 1. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas.
    Zhang Q; Liu JH; Liu JL; Qi CT; Yan L; Chen Y; Yu Q
    BMC Cancer; 2019 Nov; 19(1):1044. PubMed ID: 31690270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
    Ji SQ; Su XL; Cheng WL; Zhang HJ; Zhao YQ; Han ZX
    Urol Oncol; 2014 Feb; 32(2):153-61. PubMed ID: 23273913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer.
    Morishita A; Gong J; Nomura T; Yoshida H; Izuishi K; Suzuki Y; Kushida Y; Haba R; D'Armiento J; Masaki T
    Int J Oncol; 2010 Oct; 37(4):829-35. PubMed ID: 20811704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment.
    Sun X; Song Q; He L; Yan L; Liu J; Zhang Q; Yu Q
    Mol Cancer Ther; 2016 Oct; 15(10):2508-2520. PubMed ID: 27458140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clear cell renal cell carcinoma induces fibroblast-mediated production of stromal periostin.
    Bakhtyar N; Wong N; Kapoor A; Cutz JC; Hill B; Ghert M; Tang D
    Eur J Cancer; 2013 Nov; 49(16):3537-46. PubMed ID: 23896380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Receptor Tyrosine Kinases on Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes in Patients with Renal Cell Carcinoma and Healthy Donors.
    Tsimafeyeu I; Volkova M; Olshanskaia A; Raskin G; Aschuba S; Khochenkova Y; Bondarenko A; Khochenkov D
    Oncology; 2020; 98(4):252-258. PubMed ID: 32053815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression.
    Chen X; Wang X; Ruan A; Han W; Zhao Y; Lu X; Xiao P; Shi H; Wang R; Chen L; Chen S; Du Q; Yang H; Zhang X
    Clin Cancer Res; 2014 May; 20(10):2617-30. PubMed ID: 24647573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines.
    Korec DI; Louke DS; Breitbach JT; Geisler JA; Husbands BD; Fenger JM
    BMC Vet Res; 2021 Oct; 17(1):320. PubMed ID: 34600548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
    Nair A; Chung HC; Sun T; Tyagi S; Dobrolecki LE; Dominguez-Vidana R; Kurley SJ; Orellana M; Renwick A; Henke DM; Katsonis P; Schmitt E; Chan DW; Li H; Mao S; Petrovic I; Creighton CJ; Gutierrez C; Dubrulle J; Stossi F; Tyner JW; Lichtarge O; Lin CY; Zhang B; Scott KL; Hilsenbeck SG; Sun J; Yu X; Osborne CK; Schiff R; Christensen JG; Shields DJ; Rimawi MF; Ellis MJ; Shaw CA; Lewis MT; Westbrook TF
    Nat Med; 2018 May; 24(4):505-511. PubMed ID: 29578538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics.
    Haake SM; Li J; Bai Y; Kinose F; Fang B; Welsh EA; Zent R; Dhillon J; Pow-Sang JM; Chen YA; Koomen JM; Rathmell WK; Fishman M; Haura EB
    Clin Cancer Res; 2016 Nov; 22(22):5605-5616. PubMed ID: 27220961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.
    Schultz L; Chaux A; Albadine R; Hicks J; Kim JJ; De Marzo AM; Allaf ME; Carducci MA; Rodriguez R; Hammers HJ; Argani P; Reuter VE; Netto GJ
    Am J Surg Pathol; 2011 Oct; 35(10):1549-56. PubMed ID: 21881486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma.
    Xiao Y; Zhao H; Tian L; Nolley R; Diep AN; Ernst A; Fuh KC; Miao YR; von Eyben R; Leppert JT; Brooks JD; Peehl DM; Giaccia AJ; Rankin EB
    Cancer Res; 2019 Nov; 79(22):5758-5768. PubMed ID: 31585940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer.
    Gong J; Morishita A; Kurokohchi K; Tani J; Kato K; Miyoshi H; Inoue H; Kobayashi M; Liu S; Murota M; Muramatsu A; Izuishi K; Suzuki Y; Yoshida H; Uchida N; Deguchi K; Iwama H; Ishimaru I; Masaki T
    Int J Oncol; 2010 Jan; 36(1):101-6. PubMed ID: 19956838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NOTCH1 functions as an oncogene by regulating the PTEN/PI3K/AKT pathway in clear cell renal cell carcinoma.
    Liu S; Ma X; Ai Q; Huang Q; Shi T; Zhu M; Wang B; Zhang X
    Urol Oncol; 2013 Aug; 31(6):938-48. PubMed ID: 21993533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
    Huang J; Wang X; Wen G; Ren Y
    Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
    Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
    Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo.
    Duivenvoorden WC; Beatty LK; Lhotak S; Hill B; Mak I; Paulin G; Gallino D; Popovic S; Austin RC; Pinthus JH
    Br J Cancer; 2013 Feb; 108(2):327-33. PubMed ID: 23322200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
    Zhao Q; Caballero OL; Davis ID; Jonasch E; Tamboli P; Yung WK; Weinstein JN; ; Strausberg RL; Yao J
    Clin Cancer Res; 2013 May; 19(9):2460-72. PubMed ID: 23444225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.